9 results about "Group transformation" patented technology

The invention belongs to the technical field of biology, and discloses a non-natural pathway generation method and system based on a continuous biological template, and the method comprises the following steps: obtaining an enzymatic reaction data set, and preprocessing the enzymatic reaction data set; constructing a directed reaction diagram on the basis of the preprocessed enzymatic reaction data set, performing similar compound search on a target compound by utilizing the directed reaction diagram, and obtaining a continuous group conversion template of the similar compound in the natural enzymatic pathway by taking the searched similar compound as a starting point and combining a depth-first search mode; the continuous group conversion template is applied to a target compound in a molecular linear input specification form, and an inverse synthesis process of the target compound is simulated to generate a non-natural synthesis pathway based on the continuous group conversion template. The method not only enhances the biological feasibility and construction success rate of the approach, but also has universality, expandability and engineering potential, and provides a generalizable normal form for the field of synthetic biology.

This invention discloses a method for preparing organic sulfates, comprising the following steps: using persulfate as the sulfate source, and achieving the functional group transformation of a free radical precursor compound through the free radical anion of the sulfate ion, thereby preparing the organic sulfate. This invention uses persulfate as the source and, through a free radical addition mechanism, acts on the free radical precursor substrate. Persulfate, as a sulfate free radical anion, participates in the functional group transformation of the organic compound, resulting in the efficient synthesis of organic sulfates.

The invention belongs to the technical field of synthesis of natural products, and particularly relates to a method for divergently synthesizing a sesquiterpene quinone / hydroquinone natural product based on an allyl alcohol compound intermediate, which comprises the following steps: by taking a conjugated ketene compound 12 as a raw material, carrying out 1, 6-addition and Mukaiyama Aldol to obtain a four-membered ring compound 17; performing 4 pi electric cyclization ring opening and Michael addition to obtain a compound 19; further carrying out formylation, diazotization and Wolff rearrangement to generate a benzyl ester intermediate 28, and introducing an allyl alcohol structural unit to obtain an intermediate 31; the intermediate 31 is improved in an oxidation state to obtain a compound 36, and the compound 36 is reduced to synthesize nematode (5); and performing stereoselective hydrogenation on the intermediate 31 to obtain a compound 39, and performing functional group conversion and oxidation state adjustment to realize total synthesis of four Pleurotus griseolus natural products. The method has the advantages of simplicity, high efficiency, simplicity and convenience in operation and low cost.

The application discloses a chiral 6-hydroxypyridine oxazoline compound, a preparation method and application. The chiral 6-hydroxypyridine oxazoline compound is synthesized by using 1-cyanopyridine containing a substituent group and chiral 2-aminethanol as starting materials, and a series of novel chiral 6-hydroxypyridine oxazoline compounds are synthesized. The preparation method disclosed by the application has the advantages that the starting materials are easily obtained on the market or are easy to prepare, the cost of preparing target molecules is reduced, the synthetic route is simple and efficient, the reaction condition is mild and the operation is simple, chemical waste generated in preparation is reduced, the target molecule 6-hydroxypyridine oxazoline is a kind of novel chiral compound, has a potential application prospect of assisting transition metal catalytic asymmetric synthesis, the types of substituents of the starting materials are rich, the requirement of a synthesis strategy on the diversity of target molecules is met, and the product can be used to prepare more complex molecules through functional group transformation.

The invention discloses a synthesis method of (S)-(-)-1-(4-methoxyphenyl) ethylamine and an intermediate compound thereof, and belongs to the technical field of synthesis of medical intermediates. The method comprises the following steps: by taking p-methoxyacetophenone as an initial raw material, carrying out asymmetric reduction to obtain a chiral alcohol mixture, condensing the chiral alcohol mixture with N-p-toluenesulfonyl-L-proline, and recrystallizing to enrich an intermediate compound (R)-3A; further, the (R)-3A is subjected to alkaline hydrolysis, azidation and reduction reaction to obtain the (S)-(-)-1-(4-methoxyphenyl) ethylamine. According to the method, preparation of high-optical-purity (S)-(-)-1-(4-methoxyphenyl) ethylamine is achieved through the strategy of chiral introduction-configuration enrichment-functional group conversion, the chiral purity of the product is larger than 99%, a customized high-price catalyst is replaced with a conventional commercial reagent, a key intermediate can be recycled and reused, operation is easy and convenient, cost is controllable, environment friendliness is achieved, and the method is suitable for industrial production. The method is suitable for industrial large-scale production.

The application provides a kind of collaborative office encryption method and system based on non-commutative group transformation and perturbation mapping, method includes: extracting the feature matrix of the heterogeneous data to be encrypted, and encoding as initial group element sequence after quantization processing;From the discrete Gaussian distribution sampling error polynomial matrix superimposed to the sequence to introduce perturbation;Conjugate transformation is carried out using the system public key to obtain ciphertext polynomial matrix sequence;Random mask matrix embedding group transformation attribute is generated;Blind processing is implemented by group multiplication, and the accumulated noise norm is limited within the decryption fault boundary by cooperating with the module switching mechanism;Dynamic routing identification is generated by analyzing network path state, and encrypted transmission message is constructed;Secondary blind is carried out on load header using algebraic operator, and network layer plaintext resolvable anti-quantum encryption data is generated.The application can effectively resist quantum computing attack and flow statistical analysis, and protect the efficient and safe flow of heterogeneous data in office environment.

This invention relates to the field of chemical engineering, specifically to a method for the highly selective synthesis of high-quality ortho-vanillin. Using 3-methoxysalicylic acid as a starting material, a hydroxyl group protection reaction is performed under weakly alkaline conditions to generate compound 2. Compound 2 undergoes esterification, followed by reductive hydrogenation under a strong reducing agent to generate compound 3. In the presence of a nitrile radical catalyst, compound 3 reacts with an oxidizing agent to generate compound 4. In the presence of an acidic catalyst, compound 4 undergoes aldehyde group protection to generate compound 5. In the presence of a transition metal catalyst, the hydroxyl protecting group of compound 5 is removed to generate compound 6. Under strong acid conditions, compound 6 undergoes acetal hydrolysis to generate ortho-vanillin. This method achieves high regioselectivity and a simple process flow from the source through directional functional group transformation and protecting group strategies, avoiding the use of toxic and harmful reagents; it meets the requirements of industrial production for selectivity, environmental friendliness, and economy.

This invention belongs to the field of organic synthesis technology and relates to a method for preparing the key chiral intermediate (S)-4-(2,4-difluorophenyl)-2-(hydroxymethyl)pent-4-en-1-yl isobutyrate of posaconazole. In an electrochemical cell, 1-[1-(bromomethyl)vinyl]-2,4-difluorobenzene and methyl 2-bromo-3-isobutyryloxypropionate are reacted in the presence of a chiral nickel catalyst, followed by reduction to obtain the target product. This invention achieves asymmetric coupling of allyl and alkyl radicals through an electrochemical redox process catalyzed by a chiral nickel catalyst, constructing the core carbon skeleton and chiral center in one step. This avoids the cumbersome operations of multi-step functional group transformation and protection, and the target product exhibits high enantioselectivity and high overall yield, significantly reducing production costs and making it suitable for industrial production.

This invention belongs to the field of chemistry or medicinal chemistry, specifically relating to a method for synthesizing robecoxib. The method uses 2,3,5,6-tetrafluoroaniline and phthalic acid as raw materials, reacting them under alkaline conditions and with a catalyst to generate 5-chloro-2-(2,3,5,6-tetrafluorophenylamino)benzoic acid. This benzoic acid is then reacted sequentially with an acyl chloride reagent and a diazotizing reagent to prepare 5-chloro-1-(2,3,5,6-tetrafluorophenyl)indoline-2-one. Following a coupling reaction with an ethyl compound, 5-ethyl-1-(2,3,5,6-tetrafluorophenyl)indoline-2-one is synthesized, and finally, robecoxib is obtained after hydrolysis. In this invention, the starting materials 2,3,5,6-tetrafluoroaniline and phthalic acid are widely available. 2,3,5,6-tetrafluoroaniline is the direct structural fragment of robecoxib, while phthalic acid can be converted into the important functional groups of robecoxib, ethyl and acetic acid groups, through simple functional group transformation. This invention avoids the use of raw materials such as AlCl3, which easily generate corrosive and irritating acidic gases, thus providing a new route for the preparation of robecoxib.